The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
about
Deficient spindle assembly checkpoint in multiple myelomaWhy bortezomib cannot go with 'green'?Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyRedox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and TherapyTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureAdvances in the understanding of mechanisms and therapeutic use of bortezomibMechanisms of chemotherapy-induced behavioral toxicitiesClinical use of proteasome inhibitors in the treatment of multiple myelomaBlocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cellsBortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.Bortezomib (Velcadetrade mark) in the Treatment of Multiple MyelomaOvercoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series.A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaConstitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinomaA steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology GroupProteasome inhibition and its therapeutic potential in multiple myelomaBortezomib in the management of multiple myeloma.Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells.Proteasome inhibitors in the treatment of multiple myelomaThe use of novel agents in the treatment of relapsed and refractory multiple myelomaClinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaA phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesCCR 20th anniversary commentary: In the beginning, there was PS-341.Nuclear factor-kappaB (NF-kappaB) mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.The 26S proteasome complex: an attractive target for cancer therapyGene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicinKLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myelomaUpdate on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibEvolving treatment strategies for myeloma.
P2860
Q21560908-3EE503E9-E1BD-4E11-8739-81C63F47DD16Q24630709-27708721-2829-486A-8F83-9D218EFB47F6Q24814325-1E8421B0-9918-485D-BF03-16ABA321B2B3Q26740191-63CB9D00-BA1B-46B4-80EA-CE0C629165ABQ26746934-184E7F0B-FFA5-49F3-A135-65F2B0C31241Q26849940-829FF386-DE7F-4DF3-A5BE-39C9A8F69069Q26998870-A4684932-7171-43CA-9F7C-3006E22C9234Q28080999-B20D78BB-760E-49DC-A9D8-3D71E16F7D71Q28481321-79D6FECC-E0F4-48DE-8F2F-9E3FE72FF04EQ33308317-62EFF613-DA00-4FBD-952D-78B465C80E67Q33379044-A5274EEE-B96E-4A47-92D5-E0B0782ADE54Q33405532-D251CBAE-ADB4-4C1C-B077-F5D12B0E78B4Q33414211-14090996-37BA-424A-819F-F2849A829498Q33586505-F9C53F15-6909-4A16-93D5-72450D17C75AQ33648344-37B9D6DA-873C-4FC9-A9FF-114699E0C9C2Q33719162-D4E8D6E4-DEF1-4708-A521-CA053E69FA43Q33834630-9DDBA5A1-24F0-48AB-9AF3-54B6DAD1D916Q33916030-02F6C236-8313-4632-862A-F1D71B2DDE8CQ34225158-F602A82B-049D-44CA-B3F4-926404C560C7Q34343036-377837E9-9A98-4E36-904A-3B6118DACB76Q34418462-264EE4C8-506D-46C1-BA8E-D6A801E2CC7BQ34542978-A82D6C45-ACE9-4023-A5C4-33D8AD1DC55CQ34611676-A3FE43AF-EC8A-4203-989B-8770D37470C3Q35097319-BE560A52-7F33-4B3E-8FF0-89E898B3A1C0Q35097338-7E16D41D-520B-4FAC-A039-8ED96EF0A025Q35103364-FCE39793-F12D-4586-8A41-96471B77E59FQ35128148-F195AF74-7DF8-457A-BC48-3B0663BAF475Q35146095-D4F5082B-CAB8-4D6A-8DDB-B84D51AA4A38Q35213153-D2473DA6-0B16-4080-93C9-26B9A45DD27FQ35266125-0B64ADFF-F20D-4F56-917A-84C3610A9853Q35586471-997B59DB-3623-4AF3-8840-D7AD08BB408DQ35624079-611A58AB-A2CD-44D6-9FE3-AF40472DBF0AQ35674891-AF7C4447-7350-4E26-A67F-ABBA8BD2366FQ35776414-72CE717C-54FA-4A15-9349-9E8904F2F26BQ35836881-1D67F871-803C-4D22-9502-6662EB4E13BAQ35840019-369758DF-5A64-441A-9E42-7EFB7FC9BF28Q35868171-4CCBC49E-1F1B-469B-A163-ACEE3A78027FQ35902345-5858DC5E-AD35-4D73-A4C4-C5D654E448B8Q35905929-02027C31-2B4B-4AC8-9B0F-0B36BA039ABAQ36012354-DEC4B4D1-B44C-452B-BA18-67F3216360F6
P2860
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The proteasome inhibitor PS-34 ...... ls to chemotherapeutic agents.
@en
The proteasome inhibitor PS-34 ...... ls to chemotherapeutic agents.
@nl
type
label
The proteasome inhibitor PS-34 ...... ls to chemotherapeutic agents.
@en
The proteasome inhibitor PS-34 ...... ls to chemotherapeutic agents.
@nl
prefLabel
The proteasome inhibitor PS-34 ...... ls to chemotherapeutic agents.
@en
The proteasome inhibitor PS-34 ...... ls to chemotherapeutic agents.
@nl
P2093
P1476
The proteasome inhibitor PS-34 ...... lls to chemotherapeutic agents
@en
P2093
Amy Mikail
Cibby Altamirano
Evanthia Roussos
Hank H Yang
James R Berenson
Jason Neeser
Jeffrey M Friedman
Julian Adams
Kimberly Parker
Malka Frantzen
P304
P407
P577
2003-03-01T00:00:00Z